Shares of Intellia Therapeutics Inc (NASDAQ:NTLA) rose 10.4% during mid-day trading on Friday . The stock traded as high as $19.75 and last traded at $19.50, with a volume of 340,649 shares. The stock had previously closed at $17.66.

NTLA has been the topic of several recent analyst reports. Jefferies Group upgraded Intellia Therapeutics from a “hold” rating to a “buy” rating and set a $33.00 price objective on the stock in a report on Friday. Leerink Swann began coverage on Intellia Therapeutics in a report on Tuesday, May 31st. They set a “market perform” rating and a $32.00 price objective on the stock. Credit Suisse Group AG began coverage on Intellia Therapeutics in a report on Tuesday, May 31st. They issued an “outperform” rating and a $39.00 target price on the stock. Wedbush began coverage on Intellia Therapeutics in a report on Tuesday, May 31st. They issued an “outperform” rating and a $38.00 target price on the stock. Finally, Zacks Investment Research downgraded Intellia Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $35.50.

The firm’s market cap is $726.76 million. The firm’s 50-day moving average price is $20.63 and its 200 day moving average price is $23.53.

In other news, insider Bros. Advisors Lp Baker purchased 200,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 11th. The shares were acquired at an average price of $18.00 per share, for a total transaction of $3,600,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Institutes For Biomed Novartis purchased 277,777 shares of the firm’s stock in a transaction that occurred on Wednesday, May 11th. The stock was purchased at an average price of $18.00 per share, for a total transaction of $4,999,986.00. The disclosure for this purchase can be found here.

Intellia Therapeutics, Inc is a United States-based genome editing company focused on the development of curative therapeutics using a biological tool, CRISPR/Cas9 system. The Company’s CRISPR/Cas9 technology edits diseased genes in the human body through a single treatment course. It focuses on the therapeutic applications of CRISPR/Cas9 genome editing.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.